Wandercraft Secures $75M Series D to Propel AI Robotics and Exoskeleton Innovation

Wandercraft, a pioneer in self-balancing robotic mobility systems, has successfully closed a $75 million Series D funding round. This significant capital infusion is set to accelerate the company's ambitious plans in AI-powered robotics, including the commercialization of its personal exoskeleton, Eve, and the deployment of its industrial humanoid robot, Calvin-40. The funding arrives amidst a period of remarkable growth for Wandercraft, marked by global expansion and pivotal product innovations across clinical, consumer, and industrial sectors.

The Series D round saw major contributions from strategic investors such as Renault Group, Bpifrance, the European Investment Bank, Teampact Ventures, and Quadrant Management. This latest investment builds on the momentum from Wandercraft's previous $45 million Series C round, which notably fueled U.S. commercial expansion and led to a tenfold increase in the company's revenues. Additional participants in the Series D include LBO France, Mutuelles Impact, Managed by XAnge, Cemag Invest, Martagon Capital, and AG2R LA MONDIALE.

A key strategic partnership with Renault Group, announced prior to this funding, underscores Wandercraft's industrial ambitions. Renault, now a minority stakeholder and the first commercial partner for Calvin-40, will lend its industrial expertise to scale up the production of Wandercraft’s exoskeletons and industrial robots. Calvin-40, developed in a remarkable 40 days leveraging Wandercraft’s existing robotics platform and NVIDIA’s AI computing, is poised for production deployment at Renault factories within 40 weeks.

Wandercraft's core innovation lies in its self-balancing, hands-free robotic systems, powered by advanced AI and refined through billions of simulations. These systems are designed to restore independence by enabling upright movement without crutches or walkers. The company's flagship clinical rehabilitation system, Atalante X, has received multiple FDA clearances and is deployed in over 100 hospitals globally, facilitating millions of steps for individuals with mobility impairments. The upcoming personal exoskeleton, Eve, aims to extend this freedom to home environments, having already been showcased at high-profile events like the Olympic and Paralympic Torch Relay.

This funding round solidifies Wandercraft's position at the forefront of the rapidly evolving robotics industry, connecting advanced AI with practical applications in healthcare and industrial automation. The capital will directly support the company's mission to transform how people live, move, and work, from rehabilitation centers to factory floors, reinforcing its commitment to innovation and global market leadership.